Disclosure: This is an affiliate site. We may earn compensation from partners. Full disclosure | Medical disclaimer
Coverage is the single biggest variable in what you pay. Here is how to find out where you stand.
The difference between covered and not covered is the difference between $25 a month and $1,000 a month. No comparison of telehealth providers, no discount code and no compounded alternative matters as much as this one question, and it is worth answering before you choose anything else.
The answer depends on your specific plan's formulary, not on general rules. Two people at the same employer on different plan tiers can get completely different answers for the same medication.
What has changed in 2026 is Medicare. From July 1, the Medicare GLP-1 Bridge program covers Foundayo tablets, Wegovy injection and tablets, and the Zepbound KwikPen at $50 a month for eligible beneficiaries, through December 31, 2027. For a population that previously had no coverage at all, that is a substantial shift.
This takes about fifteen minutes and can save thousands of dollars a year. Do it before comparing providers.
Prior authorization means your insurer wants documentation before it will pay. For GLP-1s the requirements commonly include your BMI, any weight-related diagnoses, documentation that you have participated in a supervised diet and exercise program for a defined period, and sometimes evidence that you tried and failed a cheaper medication first — that last one is step therapy.
The practical implication is that your prescriber needs to submit clinical documentation, and how willing and efficient they are at this varies enormously. A telehealth platform that only handles cash-pay transactions may not do prior authorizations at all.
This is worth asking about before you enrol. Some providers offer insurance concierge services specifically to handle prior authorization and appeals. If your plan covers GLP-1s but requires PA, a provider who will fight that battle for you is worth substantially more than one charging $20 less a month.
Note that Medicare does not cover medications used solely for weight loss outside the Bridge demonstration program, so the prior authorization landscape is different for Medicare beneficiaries.
| Your situation | Typical cost | Best route |
|---|---|---|
| Commercial plan covers the category | From $25/mo | Amazon One Medical, PlushCare, Klarity, Nurx — providers that bill insurance |
| Medicare, eligible for the Bridge program | $50/mo | Medicare GLP-1 Bridge, from July 1, 2026 |
| Employer offers Teladoc weight management | $0 for the program | Teladoc — medication cost still depends on your pharmacy benefit |
| No coverage, want FDA-approved | $149-$449/mo | LillyDirect or NovoCare Pharmacy manufacturer-direct |
| No coverage, want lowest cash price | $149/mo all-in | Curex or comparable all-in compounded provider |
| Plan excludes weight-management drugs entirely | Full cash price | Manufacturer-direct — appeals will not overcome a benefit exclusion |
These sit alongside insurance and can substantially reduce what you pay. They are generally for commercially insured patients and typically exclude anyone on government insurance.
First establish which kind of no you received. A denial for missing documentation is fixable. A denial because your plan excludes weight-management medication as a benefit category is not — appealing that is spending effort on something no clinical evidence can change.
For a documentation denial, ask your insurer specifically what was missing. Common gaps are an undocumented comorbidity, no record of supervised diet and exercise participation, or no evidence of step therapy. Your prescriber can usually supply these.
Appeals do succeed, particularly when the initial submission was thin. Ask your prescriber to include your full weight history, documented comorbidities, previous weight-loss attempts and the clinical rationale rather than a bare form.
If your plan genuinely excludes the category, redirect your energy to cash-pay optimisation instead. At $149 a month for Foundayo or Wegovy tablets, self-pay is no longer the catastrophe it was two years ago.
Insurance covers FDA-approved medication. Compounded semaglutide and tirzepatide are not FDA-approved, so no commercial plan, Medicare or Medicaid will cover them, and they are not eligible for the Medicare GLP-1 Bridge program. If you have coverage, choosing a compounded provider means paying cash unnecessarily.
It depends entirely on your specific plan. Some commercial plans cover weight-management medication with a copay as low as $25 a month; others exclude the category entirely regardless of your BMI or conditions. Check your formulary for the specific product — Wegovy and Ozempic often have different coverage despite both being semaglutide.
Yes, through a temporary program. From July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge covers Foundayo tablets, Wegovy in injection and tablet form, and the Zepbound KwikPen at $50 a month for eligible beneficiaries. Outside that demonstration, Medicare does not cover medications used solely for weight loss.
It means your insurer requires clinical documentation before paying. Common requirements are your BMI, documented weight-related diagnoses, evidence of participation in a supervised diet and exercise program, and sometimes step therapy showing you tried a cheaper medication first. Your prescriber submits it, so ask any telehealth provider whether they handle prior authorizations before enrolling.
Establish which kind of denial it is. A documentation gap is fixable — ask the insurer exactly what was missing and have your prescriber supply it with a full clinical rationale. A benefit exclusion for weight-management medication as a category is not appealable on clinical grounds; in that case shift to cash-pay optimisation, where FDA-approved options now start at $149 a month.
Usually yes with commercial insurance — Novo Nordisk's Wegovy savings offer can bring eligible commercially insured patients to as little as $25 a month. Savings cards generally exclude Medicare, Medicaid and other government coverage. You cannot combine a manufacturer self-pay price with an insurance claim on the same fill.
PlushCare, Amazon One Medical, Klarity Health, Nurx and Teladoc Health all work with insurance in some form. Compounded-only providers such as Curex, TrimRx, Willow, LumiMeds and Fridays never can, because compounded products are not FDA-approved.
No, and it never will. Insurance covers FDA-approved medication, and compounded drugs are not FDA-approved. They are also ineligible for the Medicare GLP-1 Bridge program.
Usually insurance, if the category is covered — a $25 copay beats every cash price available. But if your plan has a high deductible you have not met, or requires step therapy you would rather skip, manufacturer-direct self-pay at $149 to $299 a month may be both cheaper and faster. Compare the actual figures.
Claims on this page trace to the following sources, checked on August 30, 2026.
Explore more expert guides and reviews to help you on your weight loss journey
Complete nutrition guide for GLP-1 users: what to eat, meal planning, and dietary strategies.
Evidence-based review of weight loss medications: what works, what doesn't, and expected results.
Understanding and preventing facial volume loss on GLP-1 medications with expert tips.
Complete guide to gallstone risk with GLP-1 medications: statistics, prevention strategies, and warning signs.
Understanding weight set point science and timeline for establishing permanent weight loss with GLP-1s.
Top 15 fruits for weight loss ranked by fiber, calories, and satiety—perfect for GLP-1 users.
This article summarizes general information about insurance coverage and is for informational purposes only. It is not medical, insurance, tax, or legal advice. Coverage rules vary by plan and change frequently. Confirm your own coverage directly with your insurer or Medicare before making treatment decisions. This page contains affiliate links, and we may earn compensation if you use them.
Date reviewed: August 30, 2026